Glass House Brands (GLAS) Income from Non-Controlling Interests (2022 - 2026)

Glass House Brands' (GLAS) quarterly Income from Non-Controlling Interests came in at $126000.0 in Q1 2026, down 73.42% on a QoQ basis from $474000.0 in Q4 2025.

Glass House Brands (GLAS) Income from Non-Controlling Interests (2022 - 2026) Analysis & Trends

Glass House Brands (GLAS) has 5 years of Income from Non-Controlling Interests data on file, last reported at $126000.0 in Q1 2026.

  • On a quarterly basis, Income from Non-Controlling Interests changed N/A year-over-year to $126000.0 in Q1 2026; TTM through Mar 2026 was $781000.0, a N/A change from a year earlier, with the FY2025 full-year figure at $707000.0, up 250.0% from the prior year.
  • Income from Non-Controlling Interests for Q1 2026 stood at $126000.0, down from $474000.0 in the prior quarter.
  • Over the last five years, Income from Non-Controlling Interests for GLAS reached as high as $100.4 billion in Q2 2023 and fell as low as -$24.0 billion in Q2 2022.
  • Historically, Income from Non-Controlling Interests has averaged $5.1 billion across 5 years, with a median of $62528.0 in 2023.
  • Across the five-year window, Income from Non-Controlling Interests jumped 1327.61% in 2023 and slumped 211.95% in 2024, its largest moves.
  • Year by year, Income from Non-Controlling Interests stood at -$8071.0 in 2022, then soared by 1327.61% to $99080.0 in 2023, then surged by 295.64% to $392000.0 in 2024, then advanced by 20.92% to $474000.0 in 2025, then plunged by 73.42% to $126000.0 in 2026.
  • Per Business Quant data, the three most recent Income from Non-Controlling Interests figures were $126000.0 in Q1 2026, $474000.0 in Q4 2025, and $106000.0 in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Inc. Minority (Qtr)
1 Haleon 89.28 Bn 87.42 Bn - -
2 Teva Pharmaceutical Industries 35.97 Bn 32.23 Bn 1.97 Bn -
3 Zoetis 32.42 Bn 30.48 Bn 1.62 Bn -
4 Takeda Pharmaceutical 27.48 Bn 23.42 Bn 4.39 Bn 395,346.10
5 United Therapeutics 22.89 Bn 20.73 Bn 648.10 Mn -
6 RedHill Biopharma 22.11 Bn 22.11 Bn - -
7 Viatris 20.44 Bn 18.64 Bn 1.16 Bn -
8 Neurocrine Biosciences 17.76 Bn 16.44 Bn 800.70 Mn -12.70 Mn
9 Elanco Animal Health 12.62 Bn 12.19 Bn 785.00 Mn -
10 Glass House Brands 873.84 Mn 845.91 Mn 10.02 Mn 126,000.00

Historic Data

Download Data
DateValue
Mar 31, 2026 126,000.00
Dec 31, 2025 474,000.00
Sep 30, 2025 106,000.00
Jun 30, 2025 75,000.00
Dec 31, 2024 392,000.00
Sep 30, 2024 -70,000.00
Jun 30, 2024 43,000.00
Dec 31, 2023 99,080.00
Sep 30, 2023 62,528.00
Jun 30, 2023 100.41 Bn
Mar 31, 2023 -37,000.00
Dec 31, 2022 -8,071.00
Sep 30, 2022 -7,044.00
Jun 30, 2022 -23.96 Bn
Mar 31, 2022 -22,596.00